comparemela.com

Latest Breaking News On - Helen colhoun - Page 1 : comparemela.com

Helen Colhoun, MD: Semaglutide 2.4 mg (Wegovy) Reduces Kidney Outcomes in SELECT

Helen Colhoun, MD, discusses the results of a SELECT analysis she presented at the 61st European Renal Association Congress.

Helen-colhoun
Novo-nordisk
University-of-edinburgh
European-renal-association-congress
Nature-medicine
Medical-informatics

SELECT Analysis: Semaglutide 2.4 mg (Wegovy) Reduces Negative Kidney Outcomes

Semaglutide 2.4 mg reduces kidney events in SELECT participants, showing renoprotective effects in addition to cardiovascular benefits.

United-states
American
Helen-colhoun
European-renal-association
Novo-nordisk
University-of-edinburgh-helen-colhoun
University-of-edinburgh
American-heart-association
Medical-informatics
Nature-medicine

Novo Nordisk's Wegovy lifts kidney health in obesity (NYSE:NVO)

Novo Nordisk's Wegovy lifts kidney health in obesity (NYSE:NVO)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Denmark
Stockholm
Sweden
Danish
Helen-colhoun
Reuters
University-of-edinburgh
European-renal-congress
New-nordisk
Stock-editorial
Eli-lilly

FLOW Trial Fortifies Semaglutide's Role in Chronic Kidney Disease and Type 2 Diabetes

FLOW Trial Fortifies Semaglutide's Role in Chronic Kidney Disease and Type 2 Diabetes
hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.

Helenm-colhoun
Novo-nordisk
University-of-edinburgh
European-renal-association
University-of-edinburgh-helen-colhoun
Helen-colhoun
Medical-informatics
Hispanic-white
Hazard-ratio
Confidence-interval

Genetic discovery could lead to 'prevention, delay or cure' for type 1 diabetes

Two genes associated with the immune system’s first line of defence were identified in the study and could help develop new immunotherapies.

Edinburgh
City-of
United-kingdom
Elizabeth-robertson
Paul-mckeigue
Helen-colhoun
University-of-edinburgh
Diabetes-united-kingdom
Professor-helen-colhoun
Professor-paul-mckeigue

vimarsana © 2020. All Rights Reserved.